Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

See our updated masking policy »

Stanford Health Care

Induction of LIFR confers a dormancy phenotype in breast cancer cells disseminated to the, bone marrow NATURE CELL BIOLOGY Johnson, R. W., Fingers, E. C., Olcina, M. M., Vilalta, M., Aguilera, T., Miao, Y., Merkel, A. R., Johnson, J. R., Sterling, J. A., Wu, J. Y., Giaccia, A. J. 2016; 18 (10): 1078-1089

Abstract

Breast cancer cells frequently home to the bone marrow, where they may enter a dormant state before forming a bone metastasis. Several members of the interleukin-6 (IL-6) cytokine family are implicated in breast cancer bone colonization, but the role for the IL-6 cytokine leukaemia inhibitory factor (LIF) in this process is unknown. We tested the hypothesis that LIF provides a pro-dormancy signal to breast cancer cells in the bone. In breast cancer patients, LIF receptor (LIFR) levels are lower with bone metastases and are significantly and inversely correlated with patient outcome and hypoxia gene activity. Hypoxia also reduces the LIFR:STAT3:SOCS3 signalling pathway in breast cancer cells. Loss of the LIFR or STAT3 enables otherwise dormant breast cancer cells to downregulate dormancy-, quiescence- and cancer stem cell-associated genes, and to proliferate in and specifically colonize the bone, suggesting that LIFR:STAT3 signalling confers a dormancy phenotype in breast cancer cells disseminated to bone.

View details for DOI 10.1038/ncb3408

View details for Web of Science ID 000384961700007

View details for PubMedID 27642788